Full Press Release Details
Updated Investor Presentation in Connection with
Appearance at Planet MicroCap Showcase: VEGAS 2025
Broomfield, CO, April 23, 2025 -- Aclarion, Inc., ("Aclarion"
or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary
augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, will be presenting at the Planet
MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 12:30 PM ET.
Brent Ness, Chief Executive Officer of Aclarion, will be presenting
on the Company and recent value-driving initiatives.
In conjunction with the event, Aclarion has published its updated investor
presentation, which can be found on its website at https://investors.aclarion.com/.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic
Resonance Spectroscopy ("MRS"), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms
to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported,
SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection,
Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary
signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is
entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides
critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements
that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions,
are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are
subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as
well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our
filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled "Risk Factors" in
the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus
and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are
made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as
a result of new information, future events or otherwise.